**Core tip:** Our study demonstrated the harmful role of aberrant miR-32-5p in *Helicobacter pylori* (*H. pylori*)-infected intestinal epithelial cells. Further investigation showed that SMAD family member 6 (SMAD6) was the downstream of miR-32-5p and exerted an opposite role in this process. What's more, miR-32-5p/SMAD6 contributed to transforming growth factor-β-activated kinase 1-p38 cascade activation in intestinal epithelial cells under *H. pylori* infection. These findings provide a novel insight into the pathogenesis of pediatric enteritis caused by *H. pylori*.

INTRODUCTION
============

Enteritis is a common disease of the digestive system in children among outpatients\[[@B1]\]. Etiologically, *Helicobacter pylori* (*H. pylori*) infection is one of the most important pathogenic factors to induce pediatric enteritis\[[@B2]\]. The stomach is the primary organ that is damaged by *H. pylori*. However, *H. pylori*-induced enteritis is seen with increasing incidence in recent years.

*H. pylori* infection is regarded as a class I carcinogen\[[@B3]\]. Normally, *H. pylori*-induced gastritis could lead to gastric ulcer, which is the major precancerous lesion if without treatment. Although mainly residing in stomach, *H. pylori* displays a strong ability of acid resistance. As a pathogen, *H. pylori* could attack and damage the mucosa of the digestive tract by recruiting and activating neutrophils\[[@B4]\], inducing abnormal expression of key proteins\[[@B5]\] and microRNAs (miRNAs)\[[@B6]\], and releasing cytotoxic substances\[[@B7]\]. A previous study showed that *H. pylori* infection accounted for 6% of children with duodenitis\[[@B8]\]. Moreover, Gimiga et al\[[@B9]\] found that gastritis and duodenitis contributed to half of children with upper gastrointestinal bleeding, and 36.89% of participants were diagnosed with *H. pylori* infection. These findings suggested a relatively high prevalence of children with *H. pylori* infection in the digestive system.

MicroRNAs (miRNAs) belong to non-coding RNA molecules that are abundant in eukaryotic organisms\[[@B10],[@B11]\]. MiRNAs have no ability to encode proteins, but contribute to the modulation of gene expression\[[@B11],[@B12]\]. A recent study revealed the upregulation of miR-146a and miR-155 in patients with gastritis induced by *H. pylori* infection\[[@B13]\], with the similar findings demonstrated by another research group\[[@B14]\]. Cortés-Márquez et al\[[@B14]\] further grouped the patients with gastritis by age, and found that both children and adults with *H. pylori*-induced gastritis displayed higher levels of miR-145a and miR-155. Moreover, the cancerization tendency of *H. pylori*-induced gastritis was correlated with the upregulation of miR-146a and miR-155\[[@B13],[@B14]\]. In addition, *H. pylori* infection could result in the downregulation of miRNAs. The decreased expression of miR-24-3p was shown in *H. pylori*--induced gastritis tissue samples compared with the gastritis tissues without *H. pylori* infection\[[@B15]\]. Zou et al\[[@B16]\] demonstrated that gastric epithelial cells treated with miR-3178 mimic presented alleviated inflammation induced by *H. pylori*, and miR-3178 could block *H. pylori*--induced carcinogenesis by targeting the TRAF1-NF-κB pathway. Therefore, the relationship between miRNAs and *H. pylori* infection is not positively correlated. Except for causing gastric epithelial cell damage *via* abnormal expression of miRNAs, *H. pylori* infection-induced miRNAs might contribute to intestinal epithelial cell damage. However, little is currently known about miRNAs and *H. pylori*--related enteritis.

Herein, our research revealed significant upregulation of miR-32-5p by targeting SMAD family member 6 (SMAD6) in *H. pylori*-infected intestinal epithelial cells, which aggravated the damage of *H. pylori* to the cells and might contribute to the pathogenesis of pediatric enteritis induced by *H. pylori*.

MATERIALS AND METHODS
=====================

Participants
------------

Serum samples were obtained from children with *H. pylori*-induced enteritis (*n* = 15) and healthy controls (*n* = 15), and the participants were from Shanxi Provincial People's Hospital. Procedures in this study were approved by the Ethics Committee of Shanxi University and Ethics Committee of Shanxi Provincial People's Hospital, and complied with the guidelines of Declaration of Helsinki. Both guardians of the children and the participants were informed of the purpose of the study, and signed an informed consent form.

Cell culture and H. pylori strain
---------------------------------

Human intestinal epithelial cell line HIEC-6 was cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS). Human embryonic kidney cell line HEK-293T was cultured in DMEM medium with 10% FBS. The medium and FBS were purchased from ThermoFisher Scientific (United States). *H. pylori* strain T81213-NTB (ATCC 46396) was cultured as previously described\[[@B17]\]. The concentration of *H. pylori* was adjusted to 1 × 10^9^ CFU/mL, and 1 × 10^6^ CFU/mL was used in our experiments.

Quantitative real time-polymerase chain reaction
------------------------------------------------

Serum miRNAs were extracted using a miRNeasy Serum/Plasma Kit (QIAGEN, Germany), miRNAs of cells were obtained with a miRNeasy Mini Kit (QIAGEN, Germany), and total RNA of cells was extracted using TRIzol (Takara, Japan). cDNA was acquired from the extracted RNA, and quantitative real time-polymerase chain reaction (qRT-PCR) was carried out by using a SYBR Premix Ex Taq II Kit (Takara, Japan). The expression level was calculated by using 2^-ΔΔCT^ methods. Primers used in our study are displayed in Table [1](#T1){ref-type="table"}.

###### 

Sequences of primers, siRNAs, microRNA mimic, and microRNA inhibitor used in this study

  **Gene**                             **Sequence (5'-3')**
  ------------------------------------ ------------------------------------
  miR-32-5p                            Forward: CGGTATTGCACATTACTAAGTTGCA
  Reverse: CTCGCTTCGGCAGCACA           
  U6                                   Forward: AGGGGCCATCCACAGTCTTC
  Reverse: AACGCTTCACGAATTTGCGT        
  GAPDH                                Forward: AAAAGGGCCCTGACAACTCTT
  Reverse: ACCCTGTTGCTGTAGCCAAA        
  SMAD6                                Forward: TTGTCATTTAGGGACCCTCAGC
  Reverse: TTGGCAGGAAATGCAGGTTTG       
  TNF-α                                Forward: AAGATAGGGTGTCTGGCACA
  Reverse: CCCTGAGGTGTCTGGTTTTCT       
  IL-6                                 Forward: AGCAGGCACCCCAGTTAAT
  Reverse: AATCCTTTGCAGTGGAGGGA        
  SMAD6 siRNA                          Forward: CCACAUUGUCUUACACUGAAACGGA
  Reverse: UCCGUUUCAGUGUAAGACAAUGUGG   
  si-control                           AAUUCUCCGAACGUGUCACGU
  MiR-32-5p mimic                      Forward: UAUUGCACAUUACUAAGUUGCA
  Reverse: CAACUUAGUAAUGUGCAAUAUU      
  Mimic NC                             UUCUCCGAACGUGUCACUGUU
  MiR-32-5p inhibitor                  UGCAACUUAGUAAUGUGCAAUA
  Inhibitor NC                         CAGUACUUUUGUGUAGUACAA

U6: U6 small nuclear RNA; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; SMAD6: SMAD family member 6; NC: Negative control.

Cell transfection
-----------------

SiRNAs, miRNA mimic and inhibitor, and overexpression vectors were obtained from Sangon Biotech (China). Cell transfection was carried out with Lipofectamine 3000 (Invitrogen, United States) according to the manufacturer's instructions. The sequences used are shown in Table [1](#T1){ref-type="table"}.

Detection of cell viability
---------------------------

Cell Counting Kit-8 (Beyotime, China) assay was utilized to evaluate cell viability according to the manufacturer's instructions. Cells were seeded followed by cell transfection in the presence or absence of *H. pylori*. Ten microliters of the reagents were added into each well at 37 °C for 1.5 h. The value of optical density (OD) was detected with a microplate reader (Bio-Rad, United States) at 450 nm.

Flow cytometry
--------------

After cell transfection, cells were incubated with TAK1 inhibitor NG25 (5 μmol/L, APExBIO, United States) and p38 inhibitor (10 μmol/L, Cell Signaling Technoloby, United States) in the presence or absence of *H. pylori*, harvested, and stained using an Annexin V-FITC/PI apoptosis kit (Beyotime, China) according to the manufacturer's instructions. The apoptotic rate is represented as the positive rate of cells labelled with Annexin V, and the results were analyzed by flow cytometry (Accuri C6, United States).

Luciferase assay
----------------

HEK-293T cells were used to validate the binding between miR-32-5p and SMAD6. Wild type (WT) and mutant (Mut) SMAD6 containing predicted sites with miR-32-5p were obtained from Sangon Biotech (China). After transfection for 48 h, the cells were tested using the Bio-Glo Luciferase Assay System (Promega, United States).

Western blot analysis
---------------------

Western blot analysis was performed as previously described\[[@B16]\]. Primary antibodies (mouse monoclonal to SMAD6, Santa Cruz Biotechnology, United States; rabbit monoclonal to TAK1, Abcam, United States; rabbit monoclonal to TAK1, phosphor S439, Abcam; rabbit monoclonal to p38, Abcam; rabbit monoclonal to p38, phosphor T180, Abcam; mouse monoclonal to Actin, Beyotime, China) were used in our research. The ChemDoc XRS+ System (Bio-Rad, United States) was utilized to evaluate the protein bands.

Statistical analysis
--------------------

The data are expressed as the mean ± standard deviation (SD) and analyzed by non-parametric *t*-tests using GraphPad Prism 6.0 software (GraphPad, United States). *P* \< 0.05 was considered statistically significant.

RESULTS
=======

MiR-32-5p is overexpressed in enteritis
---------------------------------------

To explore the potential role of miR-32-5p in pediatric enteritis, we first monitored the expression of miR-32-5p. After separating the serum from children with enteritis induced by *H. pylori* and healthy controls, we found that miR-32-5p was upregulated in serum of children with *H. pylori*-induced pediatric enteritis (Figure [1A](#F1){ref-type="fig"}). Next, we treated intestinal epithelial cells with *H. pylori*. The qRT-PCR results displayed that *H. pylori* led to a significant increase of miR-32-5p in intestinal epithelial cells (Figure [1B](#F1){ref-type="fig"}). These findings suggested that miR-32-5p might play a crucial role in *H. pylori*-related pediatric enteritis.

![Aberrant expression of miR-32-5p in enteritis regulates biological function of intestinal epithelial cells. A: Expression of miR-32-5p in serum of pediatric enteritis; B: Expression of miR-32-5p in intestinal epithelial cells infected by *Helicobacter pylori* (*H. pylori*); C: Cell viability measurement in intestinal epithelial cells transfected with miR-32-5p inhibitor in the presence or absence of *H. pylori*; D: Viability measurement in intestinal epithelial cells transfected with miR-32-5p mimic in the presence or absence of *H. pylori*; E: Apoptosis of intestinal epithelial cells with miR-32-5p inhibitor transfection in the presence or absence of *H. pylori*; F: Apoptosis of intestinal epithelial cells with miR-32-5p mimic transfection in the presence or absence of *H. pylori*; G: The mRNA level of TNF-α in *H. pylori*-infected intestinal epithelial cells in the presence of miR-32-5p inhibitor; I: The mRNA level of TNF-α in *H. pylori*-infected intestinal epithelial cells in the presence of miR-32-5p mimic; H: The mRNA level of IL-6 in *H. pylori*-infected intestinal epithelial cells in the presence of miR-32-5p inhibitor; J: The mRNA level of IL-6 in *H. pylori*-infected intestinal epithelial cells in the presence of miR-32-5p mimic. ^b^*P* \< 0.01. *H. pylori*: *Helicobacter pylori*.](WJG-25-6222-g001){#F1}

MiR-32-5p regulates biological behavior of H. pylori-treated intestinal epithelial cells
----------------------------------------------------------------------------------------

Next, cell transfection with miR-32-5p inhibitor or miR-32-5p mimic was utilized to verify the role of miR-32-5p in cell viability in the presence or absence of *H. pylori*. We found that *H. pylori* impaired cell viability, and miR-32-5p inhibitor partially restored the viability of *H. pylori*-infected intestinal epithelial cells (Figure [1C](#F1){ref-type="fig"}). On the contrary, miR-32-5p mimic further caused the decrease of viability of *H. pylori*-infected intestinal epithelial cells (Figure [1D](#F1){ref-type="fig"}). In parallel, *H. pylori*-infected intestinal epithelial cells with miR-32-5p inhibitor displayed a lower apoptotic rate, and miR-32-5p mimic facilitated apoptosis of *H. pylori*-infected intestinal epithelial cells (Figure [1E and F](#F1){ref-type="fig"}). In addition, we found that TNF-α was upregulated in intestinal epithelial cells infected with *H. pylori*, which was decreased by miR-32-5p inhibitor transfection and further increased by miR-32-5p mimic (Figure [1G and I](#F1){ref-type="fig"}). IL-6 expression displayed the similar trend as TNF-α (Figure [1H and J](#F1){ref-type="fig"}).

SMAD6 is the direct target of miR-32-5p
---------------------------------------

To further explore the downstream mechanism of miR-32-5p, we used TargetScanHuman 7.2 (<http://www.targetscan.org/vert_72/>) to identify SMAD6, acting as a mediator of anti-inflammatory activity, as the potential target of miR-32-5p. The luciferase assay showed that SMAD6 was the direct target of miR-32-5p (Figure [2A](#F2){ref-type="fig"}). After transfecting with miR-32-5p mimic into intestinal epithelial cells, we found that the protein level of SMAD6 was downregulated (Figure [2B](#F2){ref-type="fig"}). Next, we performed cell transfection assay to make SMAD6 overexpress and knock down (Figure [2C](#F2){ref-type="fig"}). We further found that SMAD6 overexpression ameliorated the death of intestinal epithelial cells infected by *H. pylori* (Figure [2D](#F2){ref-type="fig"}). On the contrary, SMAD6 siRNA accelerated *H. pylori*--induced cell death (Figure [2E](#F2){ref-type="fig"}). In addition, SMAD6 could partially restrain the elevation of both TNF-α and IL-6 in intestinal epithelial cells infected by *H. pylori* (Figure [2F and G](#F2){ref-type="fig"}), while SMAD6 knockdown exerted an opposite role as SMAD6 overexpression did in the expression of TNF-α and IL-6 (Figure [2H and I](#F2){ref-type="fig"}). Therefore, these findings suggested that SMAD6 played a critical role in *H. pylori*--infected intestinal epithelial cells by acting as the downstream molecule of miR-32-5p.

![SMAD family member 6 is sponged by miR-32-5p in intestinal epithelial cells. A: Luciferase assay for determining the binding between miR-32-5p and SMAD family member 6 (SMAD6); B: Protein level of SMAD6 in intestinal epithelial cells transfected with miR-32-5p mimic; C: Expression of SMAD6 in intestinal epithelial cells after SMAD6 overexpression and knockdown; D: Cell viability measurement in intestinal epithelial cells after SMAD6 overexpression in the presence or absence of *H. pylori*; E: Cell viability measurement in intestinal epithelial cells after SMAD6 knockdown in the presence or absence of *Helicobacter pylori* (*H. pylori*); F: The mRNA level of TNF-α in *H. pylori*-infected intestinal epithelial cells after SMAD6 overexpression; H: The mRNA level of TNF-α in *H. pylori*-infected intestinal epithelial cells after SMAD6 knockdown; G: IL-6 expression in *H. pylori*-infected intestinal epithelial cells after SMAD6 overexpression; I: IL-6 expression in *H. pylori*-infected intestinal epithelial cells after SMAD6 knockdown. ^a^*P* \< 0.05, ^b^*P* \< 0.01. SMAD6: SMAD family member 6; *H. pylori*: *Helicobacter pylori*.](WJG-25-6222-g002){#F2}

TGF-β1/p38 pathway is involved in apoptosis of H. pylori-infected intestinal epithelial cells
---------------------------------------------------------------------------------------------

SMAD6 is a downstream molecule of transforming growth factor-β1 (TGF-β1), and transforming growth factor-β-activated kinase 1 (TAK1)-p38 cascade activation could be executed by TGF-β1\[[@B18],[@B19]\]. We found that TGF-β1 treatment increased the apoptosis of intestinal epithelial cells, and both TAK1 inhibitor and p38 inhibitor could limit TGF-β1-induced apoptosis (Figure [3A](#F3){ref-type="fig"}). What's more, TGF-β1 led to the upregulation of phosphorylated TAK1 (p-TAK1) and phosphorylated p38 (p-p38), which could be restrained by TAK1 inhibitor (Figure [3B](#F3){ref-type="fig"}). However, TGF-β1-mediated phosphorylation of TAK1 was not inhibited by p38 inhibitor (Figure [3B](#F3){ref-type="fig"}). As shown in Figure [3C and D](#F3){ref-type="fig"}, TAK1 inhibitor and p38 inhibitor could partially increase theviability of intestinal epithelial cells infected with *H. pylori*, while miR-32-5p mimic, combined with either TAK1 inhibitor or p38 inhibitor, led to a marked decrease in the cell viability (Figure [3C](#F3){ref-type="fig"}). On the contrary, miR-32-5p further increased cell viability with either TAK1 inhibitor or p38 inhibitor under *H. pylori* infection (Figure [3D](#F3){ref-type="fig"}). Consistent with the findings in the cell viability, we found that both TAK1 inhibitor and p38 inhibitor could partially restrained the apoptosis of *H. pylori*--infected intestinal epithelial cells (Figure [3E and F](#F3){ref-type="fig"}). When miR-32-5p mimic was transfected into the cells with either TAK1 inhibitor or p38 inhibitor under *H. pylori* infection, apoptosis increased significantly (Figure [3E](#F3){ref-type="fig"}). However, miR-32-5p inhibitor transfection played an opposite role as miR-32-5p mimic did (Figure [3F](#F3){ref-type="fig"}). Thus, these results suggested that TGF-β1-TAK1-p38 cascade contributed to intestinal epithelial cell damage under *H. pylori* infection.

![Transforming growth factor-β1/p38 participates in apoptosis of intestinal epithelial cells infected by *Helicobacter pylori*. A: Apoptosis detection in transforming growth factor-β1 (TGF-β1)-treated intestinal epithelial cells in the presence of transforming growth factor-β-activated kinase 1 (TAK1) inhibitor and p38 inhibitor; B: Protein levels of total TAK1, p38, phosphorylated TAK1, and phosphorylated p38 in TGF-β1-treated intestinal epithelial cells in the presence of TAK1 inhibitor and p38 inhibitor; C: Cell viability measurement in *Helicobacter pylori* (*H. pylori*)-infected intestinal epithelial cells with TAK1 inhibitor and p38 inhibitor treatment followed by transfection with miR-32-5p mimic; D: Cell viability measurement in *H. pylori*-infected intestinal epithelial cells with TAK1 inhibitor and p38 inhibitor treatment followed by transfection with miR-32-5p inhibitor; E: Apoptosis evaluation in *H. pylori*-infected intestinal epithelial cells with TAK1 inhibitor and p38 inhibitor treatment followed by transfection with miR-32-5p mimic; F: Apoptosis evaluation in *H. pylori*-infected intestinal epithelial cells with TAK1 inhibitor and p38 inhibitor treatment followed by transfection with miR-32-5p inhibitor. ^b^*P* \< 0.01, ^d^*P* \< 0.01, ^f^*P* \< 0.01, ^g^*P* \< 0.05, ^h^*P* \< 0.01. TGF-β1: Transforming growth factor-β1; TAK1: Transforming growth factor-β-activated kinase 1; *H. pylori*: *Helicobacter pylori*.](WJG-25-6222-g003){#F3}

MiR-32-5p/SMAD6 contributes to TAK1-p38 pathway activation in intestinal epithelial cells infected by H. pylori
---------------------------------------------------------------------------------------------------------------

Next, we found the upregulation of p-TAK1 and p-p38 in intestinal epithelial cells with *H. pylori* infection (Figure [4A](#F4){ref-type="fig"}). SMAD6 is one of the inhibitory SMADs that could block TGF-β1 signaling\[[@B19]\]. Once SMAD6 overexpression plasmid was transfected into the cells, the activation of TAK1-p38 cascade was limited significantly (Figure [4B](#F4){ref-type="fig"}). Moreover, we stimulated intestinal epithelial cells with patient serum, and found that SMAD6 was downregulated (Figure [4C](#F4){ref-type="fig"}). When miR-32-5p antagonist was added into the patient serum, the downregulated expression of SMAD6 was reversed (Figure [4D](#F4){ref-type="fig"}). We also found that patient serum treatment activated TAK1 and p38 in intestinal epithelial cells compared with healthy control serum treatment (Figure [4E](#F4){ref-type="fig"}). However, miR-32-5p antagonist could result in downregulation of p-TAK1 and p-p38 in intestinal epithelial cells cultured in medium containing patient serum (Figure [4F](#F4){ref-type="fig"}).

![MiR-32-5p/SMAD family member 6 is involved in transforming growth factor-β-activated kinase 1-p38 pathway in intestinal epithelial cells. A: Detection of transforming growth factor-β-activated kinase 1 (TAK1)-p38 activation in *Helicobacter pylori* (*H. pylori*)-treated intestinal epithelial cells by Western blot; B: Inhibition of TAK1-p38 activation in *H. pylori*-treated intestinal epithelial cells with SMAD6 overexpression as revealed by Western blot; C: SMAD6 expression in intestinal epithelial cells treated with control serum and patient serum (PS); D: SMAD6 expression in PS-treated intestinal epithelial cells with miR-32-5p antagonist transfection; E: TAK1-p38 activation in PS-treated intestinal epithelial cells as revealed by Western blot; F: Inhibition of TAK1-p38 activation in PS-treated intestinal epithelial cells with miR-32-5p antagonist transfection as revealed by Western blot. CS: Control serum; PS: Patient serum; SMAD6: SMAD family member 6; TAK1: Transforming growth factor-β-activated kinase 1; *H. pylori*: *Helicobacter pylori*.](WJG-25-6222-g004){#F4}

DISCCUSION
==========

As a common digestive disease in children, enteritis could cause abdominal pain, diarrhea, and dyspepsia. If chronic enteritis results from the nonstandard treatment, children might display malnutrition, even severely affecting health and growth of children. Virus infection is regarded as the leading cause of pediatric enteritis worldwide\[[@B20],[@B21]\], which might lead to a local outbreak. However, what could not be ignored is that bacterial infection is also an important pathogenic factor resulting in pediatric enteritis. It has been reported that *H. pylori* infection displayed a remarkable correlation with pediatric enteritis\[[@B2],[@B22]\]. However, there is a lack of systematic understanding about the correlation between *H. pylori* infection and the pathogenesis of pediatric enteritis.

*H. pylori* is a common bacterium that could cause gastritis, gastric ulcer, and even gastric cancer\[[@B3],[@B7],[@B23]\]. A great deal of evidence has revealed that multiple factors contribute to *H. pylori* infection, including autophagy, miRNAs, and long non-coding RNAs (lncRNAs). *H. pylori* could promote autophagy of gastric adenocarcinoma epithelial cells, and increased antibiotic resistance of *H. pylori*-infected cells\[[@B24]\]. Yang et al\[[@B25]\] reported that miR-30d regulated autophagy-related proteins to facilitate *H. pylori* survival within cells. An increasing number of miRNAs and lncRNAs were identified by different research groups, which displayed a tight relationship with *H. pylori* infection\[[@B6],[@B14],[@B26],[@B27]\]. In the current study, we found the upregulation of miR-32-5p in serum of patients with *H. pylori*-related pediatric enteritis and *H. pylori*-infected intestinal epithelial cells. In addition, miR-32-5p inhibition could rescue intestinal epithelial cells infected with *H. pylori*, reduce *H. pylori*-induced apoptosis, and restrain the increase of inflammatory cytokines of *H. pylori*-infected cells, which inferred that miR-32-5p contributed to intestinal epithelial cell injury caused by *H. pylori* infection.

Currently, only a few studies focus on miR-32-5p, and these research findings are largely about the relationship between miR-32-5p and the pathogenesis of tumors, including cervical cancer\[[@B28]\], prostate cancer\[[@B29]\], hepatocellular carcinoma\[[@B30]\], and pancreatic cancer\[[@B31]\]. Besides, Zhang and colleagues\[[@B32]\] discovered that *Mycobacterium tuberculosis* infection led to a significant increase of miR-32-5p in macrophages, which in turns promoted *Mycobacterium tuberculosis* survival in the infected cells by targeting the downstream molecules of miR-32-5p. We found that SMAD6 was a direct target of miR-32-5p to be involved in *H. pylori*-induced intestinal epithelial cell damage. It has been demonstrated that SMAD6 is one of the two inhibitory SMADs (*e.g*., SMAD6 and SMAD7) downstream of TGF-β, and could inhibit inflammation and cell apoptosis\[[@B19],[@B33],[@B34]\]. Our findings revealed that SMAD6 overexpression could increase resistance of intestinal epithelial cells to *H. pylori*, and reduce inflammatory cytokines caused by *H. pylori*. Next, we found that TGF-β1-activated TAK1-p38 cascade contributed to *H. pylori*-induced intestinal epithelial cell injury. Luo and colleagues reported that TGF-β1 mediated *H. pylori*-related gastritis, and blocking TGF-β1 could effectively alleviate gastritis\[[@B35]\]. As we verified, inhibition of TAK1 activation and p38 activation could partially protect epithelial cells from *H. pylori* infection. Moreover, miR-32-5p inhibition further improved the protective role of TAK1 inhibitor and p38 inhibitor in *H. pylori*-infected intestinal epithelial cells.

Recently, TGF-β was determined to be involved in *H. pylori* infection. A recent study found that *H. pylori* facilitated the expression of TGF-β, and induced downregulation of cystic fibrosis transmembrane conductance regulator (CFTR) and solute linked carrier 26 gene family A6 (SLC26A6) in the duodenum\[[@B36]\]. Patients with *H. pylori*-induced duodenal ulcers displayed significantly decreased expression of CFTR and SLC26A6, which displayed a remarkable correlation with the severity of the illness\[[@B37]\]. In addition to affecting the function of intestinal epithelial cells, *H. pylori* could modulate the role of immune cells in the intestinal tract. A previous study suggested that *H. pylori* led to the upregulation of heat shock protein 60 in macrophages to promote TGF-β production, which contributed to the infiltration of regulatory T cells (Treg) to cause persistent infection\[[@B38]\]. Clinical data showed an increased number of Treg in children with *H. pylori* infection, and TGF-β had a positive correlation with the increase of Treg\[[@B39]\]. In our study, we discovered a novel manner involving TGF-β1 in which *H. pylori* infection damaged intestinal epithelial cells. Induction of miR-32-5p by *H. pylori* infection led to decreased expression of SMAD6, which weakened the inhibitory role of SMAD6 in TGF-β1-TAK1-p38 cascade activation, as demonstrated by the treatment of serum samples in intestinal epithelial cells.

Based on the above findings, we concluded that *H. pylori* infection promotes miR-32-5p upregulation to aggravate apoptosis and inflammation in intestinal epithelial cells by targeting SMAD6 and activating the TAK1-p38 pathway, highlighting a crucial role of miR-32-5p in the pathogenesis of pediatric enteritis caused by *H. pylori*.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

*Helicobacter pylori* (*H. pylori*) infection is a global issue that could cause a variety of diseases involving multiple organs. It is worth noting that the incidence of *H. pylori-*related enteritis in children increases, but the underlying mechanism is largely unknown. It has been reported that miR-32-5p is overexpressed in diseases associated with bacterial infection. However, the potential role of miR-32-5p in *H. pylori-*induced pediatric enteritis is not clear.

Research motivation
-------------------

To investigate the exact role of miR-32-5p in the pathogenesis of pediatric enteritis with *H. pylori* infection, and to find a novel target for *H. pylori-*related enteritis in children.

Research objectives
-------------------

To explore the aberrant expression and significance of miR-32-5p in children with *H. pylori-*related enteritis, especially in the damage of intestinal epithelial cells with *H. pylori* infection.

Research methods
----------------

qRT-PCR was performed to detect the expression of miR-32-5p in clinical samples and *H. pylori-*infected intestinal epithelial cells. Cell Counting Kit-8 assay and flow cytometry were conducted to evaluate the role of miR-32-5p in *H. pylori-*infected intestinal epithelial cells. TargetScanHuman database and luciferase assay were utilized to verify the potential target of miR-32-5p. Western blot was employed to clarify the underlying mechanism of miR-32-5p in influencing *H. pylori-*infected intestinal epithelial cells.

Research results
----------------

The present study discovered the aberrant expression of miR-32-5p in pediatric enteritis with *H. pylori* infection and *H. pylori-*treated intestinal epithelial cells. The *in vitro* experiments showed the significance of miR-32-5p in regulating cell viability and apoptosis of *H. pylori-*treated intestinal epithelial cells. We identified that SMAD family member 6 (SMAD6) was the direct target of miR-32-5p, and SMAD6 partially counteracted the harmful role of miR-32-5p by inhibiting the activation of TAK1-p38 cascade. However, *in vivo* assays are needed to further verify our *in vitro* findings and significance of miR-32-5p in *H. pylori-*induced pediatric enteritis.

Research conclusions
--------------------

Our research first identified the upregulation of miR-32-5p in *H. pylori-*related pediatric enteritis. Further exploration revealed that miR-32-5p inhibited SMAD6 to activate the TAK1-p38 signaling pathway, aggravating *H. pylori-*induced damage of intestinal epithelial cells. MiR-32-5p might be a potential target to overcome *H. pylori-*induced damage of intestinal epithelial cells in children.

Research perspectives
---------------------

Based on the clinical findings and *in vitro* experiments, miR-32-5p could be a novel therapeutic target for *H. pylori-*induced damage of intestinal epithelial cells in children. Further *in vivo* assays are of necessity to clarify the deleterious effects of miR-32-5p on *H. pylori-*infected intestinal epithelial cells, which is very meaningful and would contribute to clinical application.
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